User:Mr. Ibrahem/Infliximab
 | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (mouse/human) |
| Target | TNF |
| Clinical data | |
| Trade names | Remicade, Remsima, Inflectra, others |
| Other names | Infliximab-abda, infliximab-axxq, infliximab-dyyb, infliximab-qbtx |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Intravenous (IV) |
| Drug class | DMARD (biologic type)[2] |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 92% (IV, if 8% left in the syringe) |
| Metabolism | reticuloendothelial system |
| Elimination half-life | 9.5 days |
| Chemical and physical data | |
| Formula | C6428H9912N1694O1987S46 |
| Molar mass | 144190.64 g·mol−1 |
  (what is this?) (verify) | |
Infliximab, sold under the brand name Remicade among others, is a medication used to treat a number of autoimmune diseases including Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Behçet's disease.[2] It may be used together with methotrexate.[3] It is given by slow injection into a vein over at least 2 hours, with doses at six- to eight-week intervals.[2]
Common side effects include infections, acute infusion reactions, liver problems, and abdominal pain.[2] Other side effects may include cancer, reactivation of hepatitis B, worsening heart failure, and a lupus like condition.[2] It is unclear if use during pregnancy is safe.[4] Use during breastfeeding is likely safe for the baby.[3] Infliximab is a chimeric monoclonal antibody and biologic agent.[2] It seems to work by binding to and neutralizing TNF-α, preventing it from interacting with its receptors on the cell.[2]
Infliximab was approved for medical use in the United States in 1998,[2] and the European Union in August 1999.[5] Biosimilars were approved in the EU in 2013,[6] Japan in 2014,[7] and the United States in 2016.[8] In the United Kingdom it costs about 377 pounds per 100 mg as of 2020.[3] In the United States this amount costs about 500 USD as of 2020 for a biosimilar.[9]
References[edit]
- ^ a b "Infliximab Use During Pregnancy". Drugs.com. 2 July 2019. Archived from the original on 30 November 2020. Retrieved 13 August 2020.
- ^ a b c d e f g h i j "Infliximab, Infliximab-dyyb Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 15 July 2019. Retrieved 15 July 2019.
- ^ a b c BNF 79 : March 2020. London: Royal Pharmaceutical Society. 2020. p. 1153. ISBN 9780857113658.
- ^ "Infliximab Use During Pregnancy". Drugs.com. Archived from the original on 30 November 2020. Retrieved 29 October 2020.
- ^ "Remicade EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 22 October 2020. Retrieved 2 April 2020.
- ^ "EC approves first monoclonal antibody biosimilar / News / Biosimilars / Home - GaBI Online - Generics and Biosimilars Initiative". www.gabionline.net. Archived from the original on 24 October 2020. Retrieved 29 October 2020.
- ^ "Nippon Kayaku launches biosimilar Remicade in Japan". www.thepharmaletter.com. Archived from the original on 13 October 2015. Retrieved 29 October 2020.
- ^ "FDA approves Inflectra, a biosimilar to Remicade". U.S. Food and Drug Administration (FDA) (Press release). 6 December 2019. Archived from the original on 7 December 2019. Retrieved 6 December 2019.
This article incorporates text from this source, which is in the public domain.
- ^ "Infliximab-Axxq Prices and Infliximab-Axxq Coupons". GoodRx. Retrieved 29 October 2020.
